계명대학교 의학도서관 Repository

Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide

Metadata Downloads
Author(s)
Ju Hui JeongYong Jin OhYunmee LhoSun You ParkKwang-Hyeon LiuEunyoung HaYoung Ho Seo
Keimyung Author(s)
Ha, Eun Young
Department
Dept. of Biochemistry (생화학)
Journal Title
European Journal of Medicinal Chemistry
Issued Date
2016
Volume
124
Keyword
Hsp90CancerInhibitor
Abstract
The molecular chaperone Hsp90 plays an important role in cancer cell survival and proliferation by regulating the maturation and stabilization of numerous oncogenic proteins. Due to its potential to simultaneously disable multiple signaling pathways, Hsp90 has emerged as an attractive therapeutic target for cancer treatment. In this study, the design, synthesis, and biological evaluation of a series of Hsp90 inhibitors are described. Among the synthetic compounds, 6,7-dihydrothieno [3,2-c]pyridin-5(4H)-yl amide 19 exhibits a remarkable binding affinity to the N-terminus of Hsp90 in a fluorescence polarization (FP) binding assay (IC50 = 50.3 nM). Furthermore, it effectively inhibits the proliferation of H1975 non-small cell lung cancer (NSCLC) and Skbr3 breast cancer cell lines with GI50 values of 0.31 μM and 0.11 μM, respectively. Compound 19 induces the degradation of the Hsp90 client proteins including EGFR, Her2, Met, c-Raf, and Akt, and consequently promotes apoptotic cancer cell death. Compound 19 also inhibits the growth of H1975 xenografts in NOD-scid IL2R gammanull mice without any apparent body-weight loss. The immunohistologic evaluation indicates that compound 19 decreases the expression of Akt in xenograft tumor tissue via an inhibition of the Hsp90 chaperon function. Additionally, the cytochrome P450 assay indicates that compound 19 has no effect on the activities of five major P450 isoforms (IC50 > 50 μM for 1A2, 2C9, 2C19, 2D6, and 3A), suggesting that clinical interactions between compound 19 and the substrate drugs of the five major P450 isoforms are not expected. Overall, compound 19 represents a new class of Hsp90 inhibitor with its 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl-amide structure, and it has the therapeutic potential to overcome drug resistance in cancer chemotherapy.
Keimyung Author(s)(Kor)
하은영
Publisher
School of Medicine
Citation
Ju Hui Jeong et al. (2016). Targeting the entry region of Hsp90’s ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide. European Journal of Medicinal Chemistry, 124, 1069–1080. doi: 10.1016/j.ejmech.2016.10.038
Type
Article
ISSN
0223-5234
Source
https://www.sciencedirect.com/science/article/pii/S022352341630900X?via%3Dihub
DOI
10.1016/j.ejmech.2016.10.038
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/32753
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Biochemistry (생화학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.